Origins and Fundamentals of MBE – Part 2: Understanding the real importance of learning to critically analyze the validity of scientific evidence

Rate our content: Aguarde enquanto o login é efetuado

There was an error making your request, please try again!

Your evaluation is essential for us keep improving the Pebmed Portal

Want to access this and other content in full?

Register for Free

Already registered? Make your login

Login or register for free to have unlimited access to all articles, clinical cases and tools of the PEBMED Portal

The PEBMED Portal is intended for doctors and health professionals. Our contents inform recent panoramas of medicine.

If you are interested in publishing your curriculum on the internet, connecting with patients and increasing your differentials, create a free profile on AgendarConsulta, the partner site of PEBMED.

As we saw previously , the evidence-based medicine (EMB) movement was born as an educational initiative at McMaster, where young medical residents were taught to critically analyze a study. scientific. Thus, it would be possible to be more able to make scientifically informed decisions and not only based on individual opinion. Thus, the second fundamental principle of the MBE states that it provides guidance for deciding whether the evidence is more or less reliable. When referring to the confidence that one can have in relation to evidence, this principle emphasizes the existence of explicit and objective criteria that assess the methodological validity of products arising from clinical research, notably individual clinical studies, systematic reviews and guidelines.

Although there are currently several models of clinical studies, in most cases we come across the following: randomized studies, sectional studies ( or cross-sectional), case-control studies and observational cohort studies. As for the critical analysis of the methodological validity, we should check at beginning, at the middle and in The end of each study.

Read too: Evidence-based medicine: what are the practical barriers and how to apply it?

MBE

MBE

Make the best clinical decisions, update yourself. Sign up and access medical content written and peer-reviewed for free

Critical analysis of the methodological validity of randomized studies

At the beginning of the study we must first assess whether the randomization was actually performed and if so, check if there was masking or concealment. In practice, randomization involves the generation of a sequence by which study participants are randomly allocated to study groups, ensuring the unpredictability of this allocation sequence. The second masking process, which is nothing more than allocation concealment, prevents those involved in conducting a study from being able to influence (even if hypothetically) in determining which group the participants will be referred to. Randomization aims to balance known and unknown prognostic factors, making the groups comparable at the beginning of the study. In general, automated response systems are used for this purpose, most commonly a systemMBE telephone (IVRS) or digital ( IWRSMBE).

In general, randomized studies provide a table with the description of demographic data in the different study groups. This table allows us to assess whether the prognostic factors, for example associated diseases, are balanced in the groups, that is, whether randomization has fulfilled its role.

In the middle of the study we have to see if there was blinding, which consists of the impossibility of knowing which group the participant was allocated to. In general the term double blindedMBE refers to the blinding of research participants and professionals who monitor them directly during the study. However, it is also important that all those who analyze the study data and those who judge and audit the veracity of the clinical outcomes that occur throughout the study are “blind” to prevent their judgment from being influenced by the science of allocation of the participant who suffered the outcome in question. Also, in the middle of the study, it is important to check whether the co-interventions were balanced in the groups. This means that all treatments, known to be recommended for a condition in question, are being carried out in a proportionally equal manner in the studied groups. If a group receives in greater intensity, for example, a certain co-intervention that is able to reduce the rate of events considered study outcomes, the study result can be determined by this and not by the intervention being studied. Also in the middle of the study, the level of follow-up (including the assistance routines for visits and the care infrastructure) must be the same for all groups. Thus, avoiding that a group is privileged with better care that could imply a reduction in its rate of events or outcomes.

At the end of the study, we have to check if there was a analysis by intention to treat ( intention to treat), that is, whether the observed outcomes were assigned to the group to which the research participant who suffered the outcome was allocated. This does not depend on whether the participant actually received the intervention related to the group he is in or not. Any event that occurs from the moment the allocation took place is considered to be within the respective group. Another point to be seen at the end of the study is the loss to follow-up (lost of follow up), that is, the percentage of participants that in each group did not complete the study. There is no “magic number” as even a 2% loss to follow-up (1% in each group) can be considered relevant. Especially if the absolute difference in event rate between groups is small, type less than 1%. For this check, a sensitivity analysis must be performed, in which the difference in the rate of events between the groups is recalculated, in simulated scenarios.

In one scenario, it is considered that, within one of the groups, all those without follow-up suffered the outcome, whereas in the other group, it is considered that none of those without follow-up had any outcome and then the results are recalculated. In another scenario, this attribution of outcomes is inverted and the results are recalculated again. Finally, at the end of the study we should see if there was early interruption of the study for benefit, that is, before the deadline initially stipulated in the study protocol. In clinical studies, it is important to perform interim analyzes at predetermined intervals throughout the study. Such analyzes consist of checking the rate of events/outcomes in each study group during the study. The goal is to see if the tested intervention, which is supposed to have a beneficial effect, is not causing harm.

If the rate of undesirable events is very high in the group submitted to the tested intervention, above what is considered acceptable, it should be for ethical reasons to discontinue the study, assuming that the intervention does more harm than good. Now, if in an interim analysis it is observed that in the intervention group there is a much lower rate of outcomes than that observed in the control group, one should not assume that the intervention is beneficial and stop the study too soon, as this difference can be the result of chance, simply because of the small number of events. Studies terminated early for benefit tend to magnify and overestimate the real effect of the tested interventions, which may not even exist, when compared to studies that are completed according to their initial planning.

Figure 1 – Points to be checked as potential sources of methodological bias in the different phases of critical analysis of the validity of a randomized clinical trial.

As is done for randomized studies, the analysis of the methodological validity of other types of individual studies also follows this sequence (beginning, middle and end). As for the systematic reviews and for the guidelines we may use specific criteria and/or instruments for this purpose.

Read too: Artificial intelligence in evidence-based medicine: what is it like?

Recently, Gordon Guyatt himself declared, contrary to what he has advocated in the last three decades, that practitioners of EBM do not have the need to routinely make critical analyzes of evidence that inform their decisions. This is due to the fact that the number of evidence sources already critically analyzed is growing. Even so, it is important that these skills continue to be part of the MBE curriculum, as it must be known if this work was done well when we use these sources. In the coming weeks I will bring practical examples of the critical analysis of the validity of a randomized clinical trial. Please also feel free to submit suggested evidence to demonstrate these analyses.

Author:

Specialist in Cardiology-Socied. Brazilian Cardiology/AMB (2003) ⦁

References: Guyatt, G., Rennie, D., Meade, MO & Cook, DJ (2014). Users’ Guides to the Medical Literature: A Manual for Evidence Based Clinical Practice. 3rd edn. New York: McGraw-Hill. https: //jamaevidence.mhmedical.com/Book.aspx?bookId=847

  • Murad MH, Montori VM, Ioannidis JP, et al. How to read a systematic review and meta-analysis and apply the results to patient care: users’ guides to the medical literature. JAMAMBE. 2014;312(2):171-179. It hurts: 10.1001/jama.2014.5559
  • Tikkinen KAO, Guyatt GH. Understanding of research results, evidence summaries and their applicability-not critical appraisal-are core skills of medical curriculum. BMJ Evid Based Med. 2021;26(5):231-233. It hurts: 10.1136/bmjebm-2020-111542
  • Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMAMBE. 2010;303(12):1180-1187. It hurts: 10.1001/jama.2010.310
  • See more benefits of being a PEBMED Portal user: See more benefits of being a user

    7 days free with the Whitebook Application made for you, doctor, designed to bring security and objectivity to your clinical decision.

    Free access to the Nursebook Access fundamental information for your daily life such as anamnesis, semiology.

    Free Forum Access Space for exchanging experiences and constructive comments on topics related to Medicine and Health.

    Unlimited access Get access to news, studies, updates and more content written and reviewed by experts

    Test your knowledge Answer our quizzes and study in a simple and fun way

    Personalized content Receive studies, updates, new behaviors and other content segmented by specialties by email

    Note: This article has been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at the original source Click Here

    Related Posts
    Lancaster Foods’ leafy green products recall expanded thumbnail

    Lancaster Foods’ leafy green products recall expanded

    Lancaster Foods has updated their May 5 recall notice to add one product — Lancaster Brand Spinach, item #41714 — because of possible Listeria monocytogenes contamination.  The recall was initiated after notification that a random sample of a single bag of Chopped Kale Greens product with a “BEST IF USED BY May 1 2023” date
    Read More
    Preventive strategies for a healthy holiday season thumbnail

    Preventive strategies for a healthy holiday season

    Credit: Pixabay/CC0 Public Domain As the holiday season begins, it's also the season of flu and respiratory syncytial virus, or RSV. The southern parts of the U.S. are currently observing higher rates of RSV and influenza. Mayo Clinic experts expect the northern half of the country will start to see higher rates of these viruses
    Read More
    Index Of News
    Total
    0
    Share